UPDATE: Mesoblast Ltd (ASX: MSB) shares have jumped 2.8% to $2.57, raising excitement among investors as brokers forecast a potential 62% increase in value over the next year. This surge follows the company’s recent announcements indicating significant progress with its lead therapy, remestemcel-L.
In an urgent update, Mesoblast confirmed that the US Food and Drug Administration (FDA) acknowledged positive results from clinical trials. The therapy, aimed at patients suffering from chronic lower back pain linked to degenerative disc disease, has shown promising outcomes. Notably, the FDA suggested that reductions in opioid use could be included on the product label, a crucial factor in today’s healthcare landscape.
As of January 2025, many patients have reported a decrease or cessation of opioid use following treatment, marking a significant milestone in addressing the opioid crisis.
The momentum around Mesoblast is palpable. In its latest quarterly update, the company reported a net revenue of US$30 million, fueled by increasing demand for Ryoncil in the United States. Gross sales reached US$35 million, with more treatment centers coming online, enhancing patient access. Early real-world data aligns with clinical trial results, providing additional reassurance to investors.
However, risks remain. The company has faced significant financial challenges during its lengthy development process, often relying on shareholder funding to navigate regulatory hurdles. Past setbacks with the FDA have tested investor patience, and the company must now execute its sales strategy in a competitive and rapidly evolving cell-therapy market.
Despite these challenges, analysts remain optimistic. The average 12-month price target for Mesoblast shares stands at $4.16, indicating a potential upside of around 62% from current levels. TradingView data shows that all covering brokers rate Mesoblast as a strong buy, with targets ranging from $3.33 (30% upside) to a high of $5.05, reflecting a potential 97% gain.
Bell Potter has also reaffirmed its buy rating, setting a price target of $4.45, suggesting an approximate 80% increase for investors over the next year.
The question now is whether Mesoblast can maintain this trajectory and turn potential into reality. Investors are advised to stay tuned for further updates on the company’s performance and market developments.
For those considering investing, it’s crucial to evaluate the risks alongside the potential rewards. Expert Scott Phillips from Motley Fool has highlighted several stocks that he believes may currently offer more value than Mesoblast. Investors should weigh their options carefully in this fast-moving market.
As developments unfold, Mesoblast’s journey is one to watch closely, especially for those interested in the future of healthcare and innovative therapies.
